Presenter Status
Fellow
Abstract Type
Research
Primary Mentor
Jennifer Boyd, DO
Start Date
16-5-2024 12:00 PM
End Date
16-5-2024 12:15 PM
Presentation Type
Oral Presentation
Description
The use of immune checkpoint inhibitors (ICI) is increasing in the treatment of different cancers. This study investigates ICI and thyroid dysfunction in pediatric patients at Children's Mercy Kansas City. This is a retrospective chart review that looked at development of thyroid disorders in patients who received PD-1 inhibitors, PD-L1 inhibitors, or CTLA-4 inhibitors in 19 pediatric patients. Results showed that hypothyroidism developed in 3 patients who received any of these medications. Additionally, 2 patients had thyroid dysfunction prior to starting ICI therapy, and 1 of these patients developed hyperthyroidism shortly after beginning ICI therapy. Thyroid dysfunction can be seen with ICI therapy within several months of starting ICI therapy, particularly PD-1 inhibitors. Future studies should look at development of other endocrinopathies in children such as diabetes or adrenal insufficiency.
Included in
Higher Education and Teaching Commons, Medical Education Commons, Pediatrics Commons, Science and Mathematics Education Commons
Thyroid Dysfunction in Patients Receiving Immune Checkpoint Inhibitors
The use of immune checkpoint inhibitors (ICI) is increasing in the treatment of different cancers. This study investigates ICI and thyroid dysfunction in pediatric patients at Children's Mercy Kansas City. This is a retrospective chart review that looked at development of thyroid disorders in patients who received PD-1 inhibitors, PD-L1 inhibitors, or CTLA-4 inhibitors in 19 pediatric patients. Results showed that hypothyroidism developed in 3 patients who received any of these medications. Additionally, 2 patients had thyroid dysfunction prior to starting ICI therapy, and 1 of these patients developed hyperthyroidism shortly after beginning ICI therapy. Thyroid dysfunction can be seen with ICI therapy within several months of starting ICI therapy, particularly PD-1 inhibitors. Future studies should look at development of other endocrinopathies in children such as diabetes or adrenal insufficiency.
